基于性别的个体化决策方法改善骨髓增生异常综合征的精准管理:一项多中心观察性队列研究
该多中心观察性队列研究回顾性分析了13284例骨髓增生异常综合征患者,发现男女在基因突变谱和生存期上存在差异,男性中位总生存期81.3个月 vs 女性123.5个月(HR 1.40)。研究构建了纳入性别和基因组信息的预后评分系统,可使约43%-56%的患者被重新分层,提示基于性别的策略可改善个体化决策。
要点
- 男性MDS患者中位总生存期显著短于女性(81.3 vs 123.5个月,HR 1.40)。
- 七个基因突变在男性中富集,两个基因突变在女性中富集。
- 基于性别的预后评分系统可使43%-56%的患者被重新分层。
核心结论
- 研究结果提示,基于性别的策略可改善骨髓增生异常综合征患者的个体化决策过程,并应在纳入低危患者的临床试验设计中予以考虑。
研究设计与样本
- 多中心、观察性队列研究,回顾性分析13284例年龄≥18岁、符合2016年WHO标准的骨髓增生异常综合征患者。
- 患者来自EuroMDS网络(n=2025)、国际MDS预后工作组(IWG-PM;n=2387)、西班牙MDS登记处(GESMD;n=7687)和杜塞尔多夫MDS登记处(n=1185)。
- 各队列招募时间为1990年至2016年。
- 在EuroMDS队列中分析性别与基因组特征的相关性,并在IWG-PM队列中验证。
- 以总生存期为主要终点分析性别对临床结局的影响,在EuroMDS人群中分析并在其他三个队列中验证。
主要发现
- 研究纳入7792例(58.7%)男性和5492例(41.3%)女性;10906例(82.1%)为白人,2378例(17.9%)种族未报告。
- 单基因水平存在性别偏倚:七个基因突变在男性中富集(ASXL1、SRSF2和ZRSR2在两个队列中均p<0.0001;DDX41在EuroMDS队列中不可用 vs 在IWG-PM队列中p=0.0062;IDH2在EuroMDS中p<0.0001 vs 在IWG-PM中p=0.042;TET2 p=0.031 vs p=0.035;U2AF1 p=0.033 vs p<0.0001),两个基因突变在女性中富集(DNMT3A在EuroMDS中p<0.0001 vs 在IWG-PM中p=0.011;TP53 p=0.030 vs p=0.037)。
- 在奠基性基因组病变的共突变通路中存在性别偏倚:剪接相关基因主要在男性中富集(EuroMDS和IWG-PM队列中均p<0.0001),DNA甲基化主要在男性中富集(EuroMDS中p=0.046 vs IWG-PM中p<0.0001),TP53突变通路主要在女性中富集(EuroMDS中p=0.0073 vs IWG-PM中p<0.0001)。
- 在回顾性EuroMDS队列中,男性中位总生存期较差(男性81.3个月,95%CI 70.4-95.0 vs 女性123.5个月,95%CI 104.5-127.5;风险比[HR] 1.40,95%CI 1.26-1.52;p<0.0001)。
- 该结果在前瞻性验证队列中得到证实:GESMD MDS登记处男性中位总生存期54.7个月(95%CI 52.4-59.1)vs 女性74.4个月(95%CI 69.3-81.2),HR 1.30(95%CI 1.23-1.35),p<0.0001;杜塞尔多夫MDS登记处男性40.0个月(95%CI 33.4-43.7)vs 女性54.2个月(95%CI 38.6-63.8),HR 1.23(95%CI 1.08-1.36),p<0.0001。
关键数值与推荐
- 男性与女性相比,EuroMDS队列中位总生存期81.3个月 vs 123.5个月(HR 1.40,95%CI 1.26-1.52;p<0.0001),男性较差。
- GESMD MDS登记处男性与女性相比,中位总生存期54.7个月 vs 74.4个月(HR 1.30,95%CI 1.23-1.35;p<0.0001),男性较差。
- 杜塞尔多夫MDS登记处男性与女性相比,中位总生存期40.0个月 vs 54.2个月(HR 1.23,95%CI 1.08-1.36;p<0.0001),男性较差。
- 基于性别的预后评分系统重新分层比例:EuroMDS队列871/2025例(43.0%),IWG-PM队列1003/2387例(42.0%)。
- 基于性别的基因组评分系统重新分层比例:EuroMDS队列1134例(56.0%),IWG-PM队列1265例(53.0%)。
临床怎么用
- 作者认为,基于性别的策略可改善骨髓增生异常综合征患者的个体化决策过程,并应在纳入低危患者的临床试验设计中予以考虑。
- 研究创建了可基于性别个体化策略进行结局预测的网络门户。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sex is a major source of diversity among patients and a sex-informed approach is becoming a new paradigm in precision medicine. We aimed to describe sex diversity in myelodysplastic syndromes in terms of disease genotype, phenotype, and clinical outcome. Moreover, we sought to incorporate sex information into the clinical decision-making process as a fundamental component of patient individuality. METHODS: In this multicentre, observational cohort study, we retrospectively analysed 13 284 patients aged 18 years or older with a diagnosis of myelodysplastic syndrome according to 2016 WHO criteria included in the EuroMDS network (n=2025), International Working Group for Prognosis in MDS (IWG-PM; n=2387), the Spanish Group of Myelodysplastic Syndromes registry (GESMD; n=7687), or the Düsseldorf MDS registry (n=1185). Recruitment periods for these cohorts were between 1990 and 2016. The correlation between sex and genomic features was analysed in the EuroMDS cohort and validated in the IWG-PM cohort. The effect of sex on clinical outcome, with overall survival as the main endpoint, was analysed in the EuroMDS population and validated in the other three cohorts. Finally, novel prognostic models incorporating sex and genomic information were built and validated, and compared to the widely used revised International Prognostic Scoring System (IPSS-R). This study is registered with ClinicalTrials.gov, NCT04889729. FINDINGS: The study included 7792 (58·7%) men and 5492 (41·3%) women. 10 906 (82·1%) patients were White, and race was not reported for 2378 (17·9%) patients. Sex biases were observed at the single-gene level with mutations in seven genes enriched in men (ASXL1, SRSF2, and ZRSR2 p<0·0001 in both cohorts; DDX41 not available in the EuroMDS cohort vs p=0·0062 in the IWG-PM cohort; IDH2 p<0·0001 in EuroMDS vs p=0·042 in IWG-PM; TET2 p=0·031 vs p=0·035; U2AF1 p=0·033 vs p<0·0001) and mutations in two genes were enriched in women (DNMT3A p<0·0001 in EuroMDS vs p=0·011 in IWG-PM; TP53 p=0·030 vs p=0·037). Additionally, sex biases were observed in co-mutational pathways of founding genomic lesions (splicing-related genes, predominantly in men, p<0·0001 in both the EuroMDS and IWG-PM cohorts), in DNA methylation (predominantly in men, p=0·046 in EuroMDS vs p<0·0001 in IWG-PM), and TP53 mutational pathways (predominantly in women, p=0·0073 in EuroMDS vs p<0·0001 in IWG-PM). In the retrospective EuroMDS cohort, men had worse median overall survival (81·3 months, 95% CI 70·4-95·0 in men vs 123·5 months, 104·5-127·5 in women; hazard ratio [HR] 1·40, 95% CI 1·26-1·52; p<0·0001). This result was confirmed in the prospective validation cohorts (median overall survival was 54·7 months, 95% CI 52·4-59·1 in men vs 74·4 months, 69·3-81·2 in women; HR 1·30, 95% CI 1·23-1·35; p<0·0001 in the GEMSD MDS registry; 40·0 months, 95% CI 33·4-43·7 in men vs 54·2 months, 38·6-63·8 in women; HR 1·23, 95% CI 1·08-1·36; p<0·0001 in the Dusseldorf MDS registry). We developed new personalised prognostic tools that included sex information (the sex-informed prognostic scoring system and the sex-informed genomic scoring system). Sex maintained independent prognostic power in all prognostic systems; the highest performance was observed in the model that included both sex and genomic information. A five-to-five mapping between the IPSS-R and new score categories resulted in the re-stratification of 871 (43·0%) of 2025 patients from the EuroMDS cohort and 1003 (42·0%) of 2387 patients from the IWG-PM cohort by using the sex-informed prognostic scoring system, and of 1134 (56·0%) patients from the EuroMDS cohort and 1265 (53·0%) patients from the IWG-PM cohort by using the sex-informed genomic scoring system. We created a web portal that enables outcome predictions based on a sex-informed personalised approach. INTERPRETATION: Our results suggest that a sex-informed approach can improve the personalised decision making process in patients with myelodysplastic syndromes and should be considered in the design of clinical trials including low-risk patients. FUNDING: European Union (Horizon 2020 and Transcan programs), Italian Association for Cancer Research, Italian Ministry of Health, and Italian Ministry of University and Research.
引用
- A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study. Lancet Haematol. 2022. PMID: 36436542. doi:10.1016/S2352-3026(22)00323-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。